We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

P.E.M.F. Therapy of Chronic Wounds

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05493943
Recruitment Status : Not yet recruiting
First Posted : August 9, 2022
Last Update Posted : September 1, 2022
VA Long Beach Healthcare System
Southern California Institute for Research and Education
Information provided by (Responsible Party):
PEMF Systems, Inc.

Brief Summary:
To measure the effectiveness of pulsed electromagnetic fields (PEMF) as an adjunct wound care therapy.

Condition or disease Intervention/treatment Phase
Chronic Wounds Device: Pulsed ElectroMagnetic Field (PEMF) therapy Other: Pulsed ElectroMagnetic (PEMF) therapy Not Applicable

Detailed Description:

The goal of the three-arm trial is to employ application of pulsed electromagnetic fields (PEMF) directly over chronic wounds combined with standard of care local wound therapy (SOC). Three different PEMF devices, one a low power system (LP-PEMF), another a high power system (HP-PEMF) and the third a sham device that does not emit energy (S-PEMF) will be employed as adjuncts to standard wound care. The primary hypothesis to be tested is that exposure of wounds to one of the PEMF devices leads to significantly better and faster healing than the sham system.

Research Design:

An investigator initiated, prospective, double blinded parallel three arm treatment study. Subjects are randomized to receive one of the three PEMF devices (LP-PEMF, HP-PEMF or sham device) twice daily for 15 minutes directly over a wound. Initially, 40 subjects from each treatment group will be enrolled for total of 120 subjects at VA Long Beach Healthcare System (VALB) at the interim analysis. Based on the results of that analysis, one of the treatment arms will be eliminated and a follow-up study will continue with the remaining two arms. Additional 60 to 100 subjects are to be enrolled after interim analysis and the study may expand to Greater Los Angeles Medical Center. The study is expected to last 2 years.

Participating eligible subjects will be asked to come to the VALB once a week for 14 weeks and then for 2 or 3 visits over 8 more weeks. The total number of visits including the first visit could be up to 17 visits in 5 months. The study has three phases: Screening phase (2 weeks); Treatment phase (12 weeks); and Follow-up phase (8 weeks). Subjects participation in the study may last up to 22 weeks, but subjects who heal early during the Treatment phase will have a reduced period of participation based on when their wound heals.


Inclusion criteria include age ≥21 years; presence of venous leg ulcers (VLU), Diabetic foot ulcers (DFU) or Pressure Ulcers (PU); wound size between 2 and 30 cm2; no exposed joint, tendon or bone, no tunneling or sinus tracts; wound duration ≥ 6 weeks.

Each wound will be reviewed for eligibility by assessing with duplex ultrasound, skin changes, tendon/bone/joint involvement, Ankle brachial Pressure Index (ABI), BMI, Hemoglobin A1c, Albumin and other medical history.

Female subjects who are currently breast feeding or capable of conceiving and all males capable of insemination must use an acceptable form of contraception in order to participate in the study (acceptable forms of contraception include condoms for males and contraceptive pills or IUDs for women).

Findings: None

Clinical Significance: Potentially beneficial treatment option for veterans with diabetic foot ulcer, venous leg ulcers or pressure ulcers.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: 3 arms, 2 have PEMF devices, 1 Control with sham devices
Masking: Double (Participant, Care Provider)
Masking Description: Random, at time of enrollment
Primary Purpose: Treatment
Official Title: P.E.M.F. Therapy of Chronic Wounds
Estimated Study Start Date : September 15, 2022
Estimated Primary Completion Date : December 15, 2023
Estimated Study Completion Date : December 15, 2024

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: PEMF low power
PEMF therapy using a device with low pulse intensity.
Device: Pulsed ElectroMagnetic Field (PEMF) therapy
Application of PEMF using treatment coils in eproximity to the area where treatment is desired.

Active Comparator: PEMF medium power
PEMF therapy using a medium pulse intensity.
Device: Pulsed ElectroMagnetic Field (PEMF) therapy
Application of PEMF using treatment coils in eproximity to the area where treatment is desired.

Sham Comparator: PEMF Sham control
Control arm using a sham PEMF device.
Other: Pulsed ElectroMagnetic (PEMF) therapy
Control arm.

Primary Outcome Measures :
  1. Time to complete healing [ Time Frame: 12 weeks ]
    Complete re-epithelization of wound

  2. Wound closure [ Time Frame: 12 weeks ]
    Squared milimeters of wound closure

Secondary Outcome Measures :
  1. Number and type of adverse events [ Time Frame: 12 weeks ]
    Safety Endpoint

  2. Device effectiveness [ Time Frame: 12 weeks ]
    Compare the rate of effectiveness between performance of the two PEMF power levels by measuring percentage of wound closure

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Age must be at least 21 years old at the time of signing consent. 8.2 The index study ulcer size must be between 2.0 and 30.0 cm2 at the time of randomization. Measurements and photographs will to be taken after sharp debridement if performed at the Randomization Visit.
  • The index ulcer must have been present for at least 6 weeks prior to randomization.
  • If more than one ulcer is present on the target limb, the largest eligible ulcer should be deemed the study ulcer. Other ulcers close to the study ulcer are allowed and may be of any size. However, they should be > 2cm away from the study ulcer. Ulcers are allowed at other locations such as the on the contralateral limb. Other ulcers present besides the index study wound can be treated with different local care but cannot be treated with the PEMF device.
  • Only one site of application of the PEMF device is allowed and the PEMF device must be placed directly over the study ulcer.
  • Subjects to be enrolled into the VLU group must have had a duplex ultrasound study (if not done within six months prior the first screening visit) to document venous disease (deep system obstruction or reflux > 0.5 sec, or superficial system reflux > 0.5 sec, or have the characteristic hyperpigmentation and skin changes (lipodermatosclerosis) typical of venous disease.
  • Diabetic Foot Ulcer (DFU): Subjects should have with neuropathy demonstrated by monofilament testing and have Wagner grade 1 wounds without involvement of tendon, bone, or joint.
  • Pressure Ulcer (PU): PU subject wounds must be stage 3 without deep structure involvement such as bone, tendon, or joint.

Exclusion Criteria

  • Wounds due to autoimmune disease such as rheumatoid arthritis or vasculitis.
  • Exposed structures deep to the adipose layer of skin such as muscle, fascia, tendon, joint, or bone.
  • The presence of sinus tracts that have not been sufficiently marsupialized such that the wound depth cannot be assessed by gross visual inspection is an exclusion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05493943

Layout table for location contacts
Contact: Michael Davis 818-943-5414 JMDavis@pemfsystems.com
Contact: Christine Ma, MD, MPH 562-826-8000 ext 1-2889 Christine.Ma@va.gov

Sponsors and Collaborators
PEMF Systems, Inc.
VA Long Beach Healthcare System
Southern California Institute for Research and Education
Layout table for investigator information
Principal Investigator: Ian Gordon, MD, PhD VA Long Beach Healthcare System
Additional Information:

Layout table for additonal information
Responsible Party: PEMF Systems, Inc.
ClinicalTrials.gov Identifier: NCT05493943    
Other Study ID Numbers: VA Protocol 5.9
First Posted: August 9, 2022    Key Record Dates
Last Update Posted: September 1, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by PEMF Systems, Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Wounds and Injuries